Please login to the form below

Not currently logged in
Email:
Password:

SkyePharma

This page shows the latest SkyePharma news and features for those working in and with pharma, biotech and healthcare.

Consilium Strategic Communications wins Vectura account

Consilium Strategic Communications wins Vectura account

Will advise on financial and corporate PR following SkyePharma merger. Consilium Strategic Communications has been selected by Vectura to advise on its international financial and corporate PR dealings, following the completion ... of its £441m merger

Latest news

  • Vectura's Flutiform flunks phase III COPD test Vectura's Flutiform flunks phase III COPD test

    The product was originally developed by SkyePharma, which merged with Vectura earlier this year.

  • Vectura to merge with SkyePharma in £441m deal Vectura to merge with SkyePharma in £441m deal

    Will form a “one-stop shop” for specialist respiratory medicine development. UK-listed Vectura and SkyePharma have agreed to merge their operations into a single specialist respiratory medicine company. ... Vectura's chairman Bruno Angelici will hold

  • Successful partnerships in pharma: Skyepharma and Mundipharma Successful partnerships in pharma: Skyepharma and Mundipharma

    Why skills and flexibility matter more than sheer size. Skyepharma and Mundipharma collaborated on the respiratory drug Flutiform. ... Grant (pictured left) is CEO at Skyepharma and Toufar is chief marketing officer at Mundipharma International.

  • Double asthma approval in Japan lifts SkyePharma Double asthma approval in Japan lifts SkyePharma

    Regulatory wins for company’s commercial partners GSK and Kyorin. SkyePharma is celebrating after its commercial partners scored regulatory approvals in Japan for two asthma drugs. . ... SkyePharma developed technology underpinning the Ellipta dry

  • Almirall launches Solaraze in Spain

    Solarze was developed by SkyePharma and first marketed by Shire Pharmaceuticals, until Almirall acquired the product, and seven others, in a $213m deal in 2007.

More from news
Approximately 4 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Licence. $855. SkyePharma/ Vectura. Respiratory Drugs. Merger. $627. Padlock Therapeutics/ BMS.

  • A new route to market A new route to market

    My most recent assignment was at Skyepharma in Switzerland, although I have worked with both biotech and pharma companies of varying sizes, on technology transfer and licensing agreements at all stages

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics